Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Evolus (EOLS) EBITDA (2017 - 2026)

Evolus filings provide 9 years of EBITDA readings, the most recent being -$10.8 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 42.65% to -$10.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$42.9 million, a 24.12% increase, with the full-year FY2025 number at -$50.9 million, changed 0.01% from a year prior.
  • EBITDA hit -$10.8 million in Q1 2026 for Evolus, down from $111000.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $111000.0 in Q4 2025 to a low of -$23.5 million in Q2 2022.
  • Median EBITDA over the past 5 years was -$15.3 million (2025), compared with a mean of -$14.7 million.
  • Biggest five-year swings in EBITDA: crashed 375.02% in 2022 and later soared 101.58% in 2025.
  • Evolus' EBITDA stood at -$13.1 million in 2022, then rose by 11.28% to -$11.7 million in 2023, then surged by 39.86% to -$7.0 million in 2024, then soared by 101.58% to $111000.0 in 2025, then crashed by 9826.13% to -$10.8 million in 2026.
  • The last three reported values for EBITDA were -$10.8 million (Q1 2026), $111000.0 (Q4 2025), and -$15.3 million (Q3 2025) per Business Quant data.